NCT04712006WithdrawnPhase 1
Phase 1, Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Withdrawn
- Locations
- 1
- Primary Endpoint
- Serum Concentration of JNJ-64304500
Study Overview
Brief Summary
The purpose of this study is to assess the pharmacokinetic following single subcutaneous administration of Dose 1 or Dose 2 of JNJ-64304500 in healthy Chinese adult participants.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female Chinese participants whose parents and maternal and paternal grandparents are of Chinese ethnicity
- •A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and until Day 113
- •A male participant must agree not to donate sperm for the purpose of reproduction and must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and until Day 113
- •A woman must have a negative highly sensitive serum beta-human chorionic gonadotropin (hCG) at screening and a negative urine pregnancy test on Day -1 and while enrolled in this study
- •Nonsmoker or agree to smoke no more than 10 cigarettes or equivalent of e-cigarettes, or 2 cigars, or 2 pipes of tobacco per day throughout the study, if the inpatient unit allows. However, if smoking is not allowed in the inpatient unit, smokers will not be allowed to smoke while inpatient and cannot use nicotine replacement products during the inpatient period
Exclusion Criteria
- •History of any clinically significant medical illness or medical disorders the investigator considers should be exclude the participant, including (but not limited to) liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- •Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- •Had major illness or surgery, (example, requiring general anesthesia) within 12 weeks before screening, or will not have fully recovered from illness or surgery, or has surgery planned during the time the participant is expected to participate in the study or until Day 113
- •Plans to undergo non-major elective surgery within 4 weeks prior to study intervention administration through the end of the study
- •Known or suspected allergies, hypersensitivity or intolerance to JNJ-64304500 or any biologic medication, or known allergies or clinically significant reactions to murine, chimeric, or human proteins, mAbs or antibody fragments, or to any components of the formulation of JNJ-64304500 and its excipients used in this study
Arms & Interventions
Cohort 1: JNJ-64304500
Experimental
Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.
Intervention: JNJ-64304500 (Drug)
Cohort 2: JNJ-64304500
Experimental
Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.
Intervention: JNJ-64304500 (Drug)
Outcomes
Primary Outcomes
Serum Concentration of JNJ-64304500
Time Frame: Up to Day 113
Serum samples will be analyzed to determine concentrations of JNJ-64304500 using a validated, specific and sensitive immunoassay method.
Secondary Outcomes
- Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability(Up to Day 113)
- Number of Participants with Antibodies to JNJ-64304500(Up to Day 113)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese ParticipantsHealthy VolunteersNCT06674941Amgen44
Not yet recruiting
Phase 1
Biosimilarity Study of Subcutaneous Filgrastim in Healthy VolunteersHealthyNCT04958772Megalabs100
Completed
Phase 1
A Study of JNJ-73763989 in Adult Participants With Renal ImpairmentRenal ImpairmentNCT04963738Janssen Research & Development, LLC29
Not yet recruiting
Phase 1
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male SubjectsHealthy Subjects (HS)NCT06641388Akeso180
Completed
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male ParticipantsHealthy VolunteersNCT04878471Astellas Pharma Inc12